Stroke Reports
Thursday, July 17th, 2014
Wiley: 9 JUL 2014 Objective Some have argued that physicians should not presume to make thrombolysis decisions for incapacitated patients with acute ischemic stroke because the risks and benefits of thrombolysis involve deeply personal values. We evaluated the influence of the inability to consent and of personal health-related values on older adults’ emergency treatment preferences for […]
Stroke Reports
Thursday, July 17th, 2014
Neurology: 7/8/14 Objectives: The purpose of this study was to elucidate the factors that correlate with unfavorable outcomes and to develop a simple validated model for assessing risk of unfavorable outcomes in patients with minor ischemic stroke. Methods: The derivation cohort included 1,313 patients hospitalized within 72 hours after onset with an initial NIH Stroke Scale score […]
Stroke Reports
Thursday, July 17th, 2014
STROKEAHA: July 8, 2014 Background and Purpose—Prognostication tools that predict good outcome in patients with anterior circulation large vessel occlusions after endovascular therapy are lacking. We aim to develop a tool that incorporates clinical and imaging data to predict outcomes after endovascular therapy. Methods—In a derivation cohort of anterior circulation large vessel occlusion stroke patients treated […]
Stroke Reports
Thursday, July 17th, 2014
Neurology: May 21, 2014 Objective: To determine the cumulative rate and characteristics of recurrent thromboembolic events after acute ischemic stroke in patients with cancer. Methods: We retrospectively identified consecutive adult patients with active systemic cancer diagnosed with acute ischemic stroke at a tertiary-care cancer center from 2005 through 2009. Two neurologists independently reviewed all electronic records to ascertain […]
Stroke Reports
Thursday, July 17th, 2014
The Lancet, Early Online Publication, 23 May 201. Background Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to […]
Stroke Reports
Saturday, July 5th, 2014
J NeuroIntervent Surg: 6/26/14 Abstract Background In acute stroke management, time efficiency in the continuum of patient management is critical. We aimed to determine if implementation of system improvements at our institution translated to reduced picture-to-puncture (P2P) times over a 6-year period. Methods We conducted a single-center retrospective analysis using a prospective acute stroke database of patients treated […]
Stroke Reports
Saturday, July 5th, 2014
CIRCOUTCOMES: June 24, 2014 Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims Background—The accuracy of stroke diagnosis in administrative claims for a contemporary population of Medicare enrollees has not been studied. We assessed the validity of diagnostic coding algorithms for identifying stroke in the Medicare population by linking data from […]
Stroke Reports
Saturday, July 5th, 2014
International Journal of Health Geographics: 6/17/14 Background Evidence linking outdoor air pollution and incidence of ischemic stroke subtypes and severity is limited. We examined associations between outdoor PM10 and NO2 concentrations modeled at a fine spatial resolution and etiological and clinical ischemic stroke subtypes and severity of ischemic stroke. Methods We used a small-area level ecological study design […]
Stroke Reports
Saturday, July 5th, 2014
Wiley: 12 JUN 2014 Conflict of interest: Dr. Amarenco has received research funding from Pfizer, AstraZeneca, Merck, Sanofi-Aventis, and BMS; speaker fees from Pfizer, Sanofi-Aventis, Bayer, Boehringer-Ingelheim, AstraZeneca, and Otsuka Pharmaceutical; and honoraria from Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Merck, Kowa, Lundbeck, Boston Scientific, Edwards, Bayer, and Boehringer-Ingelheim. Dr. Abboud has no conflicts of interest to […]
Stroke Reports
Saturday, July 5th, 2014
Wiley: 2 JUN 2014 Funding: Professor Thorsten Steiner has received honoraria from Boehringer, Bayer, and BMS–Pfizer. Professor Bo Norrving has acted as consultant for Bayer HealthCare, Servier, Syngis, Daichii Sankyo and Allergan, and has received royalties for a book published by Karolinska University Press. Professor Graeme Hankey has received honoraria for serving on the executive committees […]
